Astellas Pharma disclosed its IFRS results on 4 November and raised its net income forecast for the current fiscal year from the previous forecast of ¥300 billion to ¥350 billion. Taking interim results and the outlook together, it added to its forecast for record-high profit.
Astellas Pharma announced its earnings summary for the current fiscal year, reporting cumulative net income of ¥241.6 billion for the second quarter (2Q) covering April–September, up 63.7% year on year. Revenue increased from ¥935,621 million to ¥1,270,861 million, while the operating margin rose from 20.0% to 21.0% at present.
The full-year net income forecast was raised from the previous ¥300 billion to ¥350 billion, with profit expected to increase approximately 20.1% from the previous fiscal year. Accordingly, consolidated net income for the second half is calculated to decline year on year and is estimated at approximately ¥108.3 billion.
In the most recent 3-month period, net income for July–September was ¥99.8 billion, up 26.1% year on year, with both revenue and the operating margin improving.